跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT01880632
NCT01880632Unknown2 期

A Multicenter, Single Arm, Open-label Trial of Oxaliplatin Plus Capecitabine (XELOX) in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma

Shanghai Zhongshan Hospital1 个研究点 分布在 1 个国家目标入组 55 人开始时间: 2013年7月最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
2 期
发起方
入组人数
55
试验地点
1
主要终点
the response rate of XELOX in the neoadjuvant setting of LAGC
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

  1. Target population:locally advanced gastric adenocarcinoma (LAGC, cT2~3/N+M0,or cT4aN+M0);no previous chemo or radio therapy.
  2. Primary objective:Response rate of XELOX in the neoadjuvant setting of LAGC.

Secondary objectives:

  • The progression free survival (PFS) in the perioperative treatment of locally advanced gastric adenocarcinoma (cT3/N+M0,or cT4aN+M0);
  • percentage of pathological response ; percentage of grade 3 or 4 adverse events as safety profile of perioperative treatments;
  • D2 resection -rate after neoadjuvant chemotherapy of XELOX;
  • Overall survival;
  • QOL during the whole period of treatment.
  1. Trial design:This is a multicenter, single arm, open-label, phase II study to evaluate the efficacy and safety of Oxaliplatin plus capecitabine(XELOX) in the perioperative treatment of locally advanced gastric adenocarcinoma in combination with D2 resection.
  2. Treatment plan:Patients will be given the perioperative chemotherapy as below once recruited:Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow: Capecitabine 1000 mg/m2 ，bid,d 1~14 every 3 weeks(treatment for 2 weeks and rest 1 week)Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks.
  3. Number of subjects:50 patients.Number of centers 5 sites, which have the high volume of gastric operations in China, more than 500 per year.

详细描述

  1. Disease specific inclusion criteria:
  • Histologically documented gastricadenocarcinoma with Lauren classification Clinically diagnosed stage T2-3/N+M0,orT4aN+M0 according to CT/MRI scan, and resectable
  • Measurable disease is required
  • Karnofsky score 80%.
  • Physical condition and adequate organ function to ensure the success of abdominal surgery.
  • Life expectancy ≥12 weeks.
  • Adequate hematological function: Neutrophil count ≥ 1.5 × 109/L, Platelets ≥ 100 × 109/L and Hemoglobin ≥8g/dL .Adequate liver function: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); AST (SGOT) and ALT (SGPT) < 2.5 × ULN in the absence of liver metastases, or < 5 × ULN in case of liver metastases. ALP ≤ 2.5 × upper limit of normal (ULN); ALB ≥30g/L.

Adequate renal function: Serum creatinine ≤ 1.25 x ULN, and creatinine clearance ≥ 60 ml/min.

  • Female subjects should not be pregnant or breast-feeding.
  • No serious concomitant disease that will threaten the survival of patients to less than 5 years.
  1. General inclusion criteria:
  • Male or female. Age ≥ 18 years and ≤75 years
  • Written (signed) informed consent.
  • Able to comply with study and follow-up procedures.
  • Good compliance with the treatment plan。
  • Consent to provide tissue sample。

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Histologically documented gastricadenocarcinoma with Lauren classification Clinically diagnosed stage T2-3/N+M0,orT4aN+M0 according to CT/MRI scan, and resectable
  • •Measurable disease is required
  • •Karnofsky score 80%.
  • •Physical condition and adequate organ function to ensure the success of abdominal surgery.
  • •Life expectancy ≥12 weeks.
  • •Adequate hematological function: Neutrophil count ≥ 1.5 × 109/L, Platelets ≥ 100 × 109/L and Hemoglobin ≥8g/dL .Adequate liver function: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); AST (SGOT) and ALT (SGPT) < 2.5 × ULN in the absence of liver metastases, or < 5 × ULN in case of liver metastases. ALP ≤ 2.5 × upper limit of normal (ULN); ALB ≥30g/L.Adequate renal function: Serum creatinine ≤ 1.25 x ULN, and creatinine clearance ≥ 60 ml/min.
  • •Female subjects should not be pregnant or breast-feeding.
  • •No serious concomitant disease that will threaten the survival of patients to less than 5 years.
  • •Male or female.
  • •Age ≥ 18 years and ≤75 years
  • •Written (signed) informed consent.
  • •Able to comply with study and follow-up procedures.
  • •Good compliance with the treatment plan.
  • •Consent to provide tissue sample.

排除标准

  • •Pregnant or lactating (in case of potentially childbearing woman, pregnancy test is positive)
  • •Patients of child-bearing age or the potential to father a child who refuse to use adequate contraception
  • •Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator.
  • •History of another malignancy in the last 5 years with the exception of the following:
  • •Any previous palliative, adjuvant or neoadjuvant chemotherapy and/or radiotherapy. Prior treatment for locally advanced or metastatic gastric cancer. Any metastatic disease will render patient ineligible according to AJCC staging manual.
  • •Distant metastases (M1) including distant nodal Groups (peripancreatic, para-aortic, portal, retroperitoneal, mesenteric node, by CT/MRI, or PET/CT
  • •Treatment within the last 30 days with any investigational drug. Concurrent administration of any other cancer therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy.
  • •Active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy.
  • •Poorly controlled diabetes mellitus with fasting blood sugar > 18 mM. Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
  • •History of significant neurological or mental disorder, including seizures or dementia, which would interfere compliance and sign of consent inform. any history of hypersensitivity to 5-fluorouracil or platinum and other investigational drug
  • •Ileus, chronic inflammatory intestinal disease or extensive resection of the small intestine and other disorders which limit drug reabsorption. This includes gastric dumping syndrome, indications of accelerated passage through the small intestine, indications of reabsorption disorders after intestinal surgery
  • •Unstable, persistent cardiac disease despite medicinal treatment, myocardial infarction within 6 months before the start of the trial
  • •Organ transplant patient need immunosuppression treatment.
  • •Previous surgery on primary tumour; Prior palliative surgery (open and closure, passage operation)
  • •Any other type of tumour (e.g. leiomyosarcoma, lymphoma) or a secondary malignancy, excepting basal cell skin carcinoma or basal cell carcinoma in situ of the cervix which have already been successfully treated
  • •Symptomatic peripheral neuropathy NCI CTC version> 3.0 grade.
  • •Patients under anticoagulant therapy with warfarin or other coumarines are excluded from participation.

研究组 & 干预措施

XELOX

Experimental

Clinically diagnosed stage T2-3/N+M0,orT4aN+M0 according to CT/MRI scan, and resectable

干预措施: XELOX (Drug)

结局指标

主要结局

the response rate of XELOX in the neoadjuvant setting of LAGC

时间窗: 6 months after the last subject participating in

the response rate evaluation will be based on tumor assessment with follow-up, including chest and upper-abdominal During preoperative treatment period, CT scan will be performed every 6 -8 weeks (2 cycles after)., brain MRI and bone scan (ECT) will be performed if any suspected symptoms occur.

次要结局

  • the progression free survival (PFS) in the perioperative treatment of locally advanced gastric adenocarcinoma (cT2-3/N+M0,or cT4aN+M0)(42 months after the last subject participating in)
  • QOL during the whole period of treatment(1 years after the last date of treatment)
  • percentage of pathological response(10 months after the last subject participating in)
  • Overall survival(3 years after the last subject participating in)
  • Percentage of grade 3 or 4 adverse events as safety profile of perioperative treatments(1 month after the last date of treatment)

研究者

发起方
Shanghai Zhongshan Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Tianshu Liu

Director of Medical oncology derpartment

Shanghai Zhongshan Hospital

研究点 (1)

Loading locations...

相似试验

已完成
3 期
Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric CancerGastric Cancer
NCT01815853Sun Yat-sen University620
已完成
1 期
Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel
NCT05529667Yonsei University15
已完成
3 期
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
NCT02370498Merck Sharp & Dohme LLC592
招募中
2 期
Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric AdenocarcinomaGastroEsophageal CancerSOXFruquintinibGastric Cancer
NCT05122091Guangxi Medical University53
招募中
1 期
Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ CancerMetastatic Gastroesophageal Junction Adenocarcinoma
NCT06329973Henan Cancer Hospital70